Immune-Related Adverse Events: Pneumonitis

Checkpoint inhibitors are part of the family of immunotherapies and are increasingly being used in a wide variety of cancers. Immune-related adverse events pose a major challenge in the treatment of cancer patients. Pneumonitis is a rare immune-related adverse event that presents in distinct pattern...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Linda, Altan, Mehmet, Shannon, Vickie R., Sheshadri, Ajay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161534/
https://www.ncbi.nlm.nih.gov/pubmed/32301020
http://dx.doi.org/10.1007/978-3-030-41008-7_13
_version_ 1783522971592163328
author Zhong, Linda
Altan, Mehmet
Shannon, Vickie R.
Sheshadri, Ajay
author_facet Zhong, Linda
Altan, Mehmet
Shannon, Vickie R.
Sheshadri, Ajay
author_sort Zhong, Linda
collection PubMed
description Checkpoint inhibitors are part of the family of immunotherapies and are increasingly being used in a wide variety of cancers. Immune-related adverse events pose a major challenge in the treatment of cancer patients. Pneumonitis is a rare immune-related adverse event that presents in distinct patterns. The goal of this chapter is to instruct readers on the incidence and clinical manifestations of pneumonitis and to offer guidance in the evaluation and treatment of patients with pneumonitis.
format Online
Article
Text
id pubmed-7161534
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-71615342020-04-16 Immune-Related Adverse Events: Pneumonitis Zhong, Linda Altan, Mehmet Shannon, Vickie R. Sheshadri, Ajay Immunotherapy Article Checkpoint inhibitors are part of the family of immunotherapies and are increasingly being used in a wide variety of cancers. Immune-related adverse events pose a major challenge in the treatment of cancer patients. Pneumonitis is a rare immune-related adverse event that presents in distinct patterns. The goal of this chapter is to instruct readers on the incidence and clinical manifestations of pneumonitis and to offer guidance in the evaluation and treatment of patients with pneumonitis. 2020-04-17 /pmc/articles/PMC7161534/ /pubmed/32301020 http://dx.doi.org/10.1007/978-3-030-41008-7_13 Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Zhong, Linda
Altan, Mehmet
Shannon, Vickie R.
Sheshadri, Ajay
Immune-Related Adverse Events: Pneumonitis
title Immune-Related Adverse Events: Pneumonitis
title_full Immune-Related Adverse Events: Pneumonitis
title_fullStr Immune-Related Adverse Events: Pneumonitis
title_full_unstemmed Immune-Related Adverse Events: Pneumonitis
title_short Immune-Related Adverse Events: Pneumonitis
title_sort immune-related adverse events: pneumonitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161534/
https://www.ncbi.nlm.nih.gov/pubmed/32301020
http://dx.doi.org/10.1007/978-3-030-41008-7_13
work_keys_str_mv AT zhonglinda immunerelatedadverseeventspneumonitis
AT altanmehmet immunerelatedadverseeventspneumonitis
AT shannonvickier immunerelatedadverseeventspneumonitis
AT sheshadriajay immunerelatedadverseeventspneumonitis

Ejemplares similares